Filing Analysis
Cypherpunk Technologies entered into an Asset Purchase Agreement with Moria Mining, LLC and Winklevoss Treasury Investments, LLC (WTI) to acquire mining equipment and hosting agreements. The $33.3M transaction is funded via a pre-funded warrant issued to WTI, a major shareholder that already owns 19.9% of the company.
🚩 Red Flags
- Related-party transaction: The seller's affiliate (WTI) is a major shareholder owning 19.9% of the company.
- Significant dilution: The issuance of 43.29 million shares at a nominal $0.001 exercise price represents massive potential dilution for existing shareholders.
- Concentration of control: WTI holds significant voting power and board representation, and the transaction involves a pre-funded warrant that bypasses immediate cash inflow.
- Regulatory/Compliance risk: The company is required to seek shareholder approval for the issuance of shares exceeding the 5% Nasdaq threshold.
📋 Key Facts
- Transaction Date: August 17, 2026.
- Purchase Price: $33,333,333 via a pre-funded warrant to purchase 43,290,042 shares of common stock.
- Warrant Terms: Exercise price of $0.001 per share; no expiration date.
- Beneficial Ownership: WTI (the Seller's affiliate) already owns 19.9% of the company.
- Shareholder Vote: The company must seek stockholder approval for the issuance of warrant shares exceeding 5.37M shares (approx. 4.99% of outstanding stock).
- Board Representation: WTI has the right to appoint two directors (Mr. William McEvoy and Mr. Khing Oei).
Cypherpunk Technologies Inc. received a deficiency notice from Nasdaq because its common stock closed below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has until January 19, 2027, to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice/Non-compliance with minimum bid price requirement.
- Explicit mention of a potential reverse stock split to regain compliance.
- Uncertainty regarding the ability to regain compliance within the allotted timeframe.
📋 Key Facts
- Received 'Closing Bid Price Deficiency Letter' from Nasdaq on July 20, 2026.
- Violation of Nasdaq Listing Rule 5550(a)(2) due to closing bid price being below $1.00 for 30 consecutive business days.
- The company has a 180-day compliance period ending January 19, 2027.
- Potential for an additional 180-calendar day extension if market value requirements are met and the company files intent to cure (e.g., via reverse stock split).
- The deficiency does not currently affect current listing or trading status.
Cypherpunk Technologies Inc. held its 2026 Annual Meeting of Stockholders on June 18, 2026. The filing reports the results of stockholder votes regarding director elections, executive compensation, and the ratification of the company's independent auditor.
📋 Key Facts
- Annual Meeting held on June 18, 2026.
- Will McEvoy was elected to Class III director (24,927,307 votes for).
- Nissim Mashiach was elected to Class III director (22,174,332 votes for).
- Stockholders approved executive compensation on an advisory basis.
- EisnerAmper LLP was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2026.
Cypherpunk Technologies Inc. (CYPH) has regained compliance with Nasdaq's minimum bid price requirement (Listing Rule 5550(a)(2)) as of May 21, 2026, following a deficiency notice received on March 4, 2026.
📋 Key Facts
- Company received a Closing Bid Price Deficiency Letter from Nasdaq on March 4, 2026.
- The deficiency was caused by the common stock closing bid price falling below $1.00 for 30 consecutive business days.
- Nasdaq notified the Company on May 21, 2026, that it has regained compliance.
- The matter is now officially closed by Nasdaq.
Cypherpunk Technologies Inc. announced its financial results for the fiscal quarter ended March 31, 2026. The announcement was made via a press release furnished as an exhibit to the filing.
📋 Key Facts
- Financial results announced for the quarter ended March 31, 2026
- Filing includes Item 2.02 (Results of Operations and Financial Condition)
- Press release dated May 14, 2026, was furnished as Exhibit 99.1
- The report was signed by President & CEO Douglas E. Onsi
Four members of Cypherpunk Technologies Inc.'s Board of Directors, including Class I and Class III directors, announced their retirement and will not stand for re-election at the 2026 Annual Meeting. The departing directors are Dr. Christopher Mirabelli, Dr. Joseph Loscalzo, Dr. Richard Schilsky, and Dr. James Cavanaugh.
🚩 Red Flags
- Simultaneous departure of four board members represents a significant turnover in corporate governance.
- Potential loss of institutional knowledge as multiple committee members exit at the same time.
📋 Key Facts
- On April 7, 2026, four directors (Mirabelli, Loscalzo, Schilsky, and Cavanaugh) notified the company of their intent to retire.
- The resignations are effective immediately prior to the 2026 Annual Meeting of Stockholders.
- The departures include two Class III directors (Mirabelli and Loscalzo) and two Class I directors (Schilsky and Cavanaugh).
- The company explicitly stated that none of the departures were due to disagreements with the Company on any matter relating to operations, policies, or practices.
Cypherpunk Technologies Inc. announced its financial results for the fiscal year ended December 31, 2025. The announcement was made via a press release furnished as an exhibit to the filing.
📋 Key Facts
- Reported fiscal year 2025 financial results on March 16, 2026
- Filed under Item 2.02 (Results of Operations and Financial Condition)
- Douglas E. Onsi is identified as the President and CEO
- The company maintains its listing on the Nasdaq Capital Market under the ticker CYPH
Cypherpunk Technologies Inc. received a deficiency notice from Nasdaq on March 4, 2026, because its common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. The company has 180 days, or until August 31, 2026, to regain compliance by maintaining a $1.00 bid price for at least 10 consecutive business days.
🚩 Red Flags
- Nasdaq delisting notice for minimum bid price deficiency.
- Potential for a reverse stock split to maintain listing.
- Failure to maintain a $1.00 share price indicates significant market devaluation.
📋 Key Facts
- Received Nasdaq Closing Bid Price Deficiency Letter on March 4, 2026.
- Common stock bid price was below $1.00 for 30 consecutive business days.
- The company has until August 31, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2).
- A second 180-day extension may be available if the company meets other listing requirements.
- The company explicitly mentioned a reverse stock split as a potential cure for the deficiency.
Cypherpunk Technologies Inc. has restructured a consulting agreement with CoinXit Ltd., resulting in the issuance of 5,448,157 RSUs to satisfy prior obligations and new requirements. The recipient, CoinXit, is controlled by Khing Oei, who serves as the Company's Chairman and was appointed via an investor designation from Winklevoss Treasury Investments, LLC.
🚩 Red Flags
- Significant related-party transaction: The RSU recipient (CoinXit) is controlled by the Company's Chairman.
- Complex equity restructuring: The cancellation of previous RSUs to issue a larger consolidated grant to a related party can be used to mask dilution or shift compensation structures.
- Potential for significant future dilution due to the large volume of RSUs being issued to an insider-controlled entity.
📋 Key Facts
- The Company granted 5,448,157 RSUs to CoinXit Ltd. on December 23, 2025, under the 2025 Equity Incentive Plan.
- This grant replaces and consolidates a previous grant of 2,411,700 RSUs (November 2025) and an obligation for an additional 3,036,457 RSUs.
- RSUs vest over a 36-month period starting October 8, 2026 (12/36ths upfront, then 1/36th monthly).
- Khing Oei is the sole director, employee, and stockholder of CoinXit Ltd.
- Khing Oei serves as the Chairman of the Board at Cypherpunk Technologies Inc. via an 'Investor Designee' appointment from Winklevoss Treasury Investments, LLC (WTI).
Cypherpunk Technologies Inc. announced a significant purchase of Zcash (ZEC), increasing its total holdings to 290,062.67 ZEC. The company spent approximately $29 million in this transaction at an average price of $514.02 per ZEC.
🚩 Red Flags
- Significant concentration risk: The company is allocating substantial capital ($29M) into a single highly volatile digital asset (Zcash).
- Volatility exposure: The stock price of CYPH will likely become highly correlated with the price of ZEC.
📋 Key Facts
- Purchased an additional 56,418.09 ZEC on December 30, 2025.
- Transaction value was approximately $29 million.
- Average purchase price for the new tranche: $514.02 per ZEC.
- Total aggregate holdings: 290,062.67 ZEC.
- Cumulative average cost basis: $334.41 per ZEC.
- Current holdings represent an estimated 1.76% of the total circulating ZEC network supply.
Cypherpunk Technologies Inc. (formerly Leap Therapeutics) held a special meeting on December 15, 2025, where stockholders approved several major corporate actions, including a reverse stock split and an increase in authorized shares. The company also reported regaining compliance with Nasdaq's minimum bid price requirement.
🚩 Red Flags
- Approval of a reverse stock split (often used to artificially boost share price for listing compliance).
- Significant increase in authorized shares (potential dilution).
- Approval of private placement issuance (potential immediate dilutive event).
- History of Nasdaq minimum bid price non-compliance.
📋 Key Facts
- Stockholders approved the adoption of the 2025 Equity Incentive Plan covering up to 31,454,785 shares.
- The Charter was amended to increase authorized shares from 250,000,000 to 500,000,000 (490M Common, 10M Preferred).
- Stockholders approved a reverse stock split proposal with 36,314,864 votes in favor.
- Stockholders approved a private placement issuance proposal.
- Nasdaq notified the company on December 11, 2025, that it has regained compliance with the $1.00 minimum bid price requirement.
Cypherpunk Technologies Inc. entered into a waiver and modification agreement with Winklevoss Treasury Investments, LLC regarding a previously issued common warrant. The agreement modifies share reservation covenants to facilitate the company's $200 million at-the-market (ATM) equity offering program.
🚩 Red Flags
- Potential for significant dilution via the $200 million ATM program.
- Explicit mention of a potential 'reverse stock split' of at least 1:5 as a trigger condition, suggesting the company may be working to maintain Nasdaq compliance or manage share price.
- The modification involves a large block of shares (57.1M) being released for dilution purposes.
📋 Key Facts
- Agreement dated November 19, 2025, with Winklevoss Treasury Investments, LLC ('Winklevoss Capital').
- Winklevoss Capital waived the 'Share Reservation Covenant' for 57,182,378 shares (Restricted Warrant Shares).
- The waiver allows these shares to be used by the Company for its $200 million at-the-market (ATM) equity offering program.
- Exercise of Restricted Warrant Shares is deferred until after: (i) authorized Common Stock reaches 490,000,000 shares OR (ii) a reverse stock split of at least 1:5 ratio occurs.
Cypherpunk Technologies Inc. (formerly Leap Therapeutics, Inc.) announced a significant additional purchase of Zcash (ZEC) totaling $18 million. This acquisition increases the company's total holdings to 233,644.56 ZEC, representing 1.43% of the total Zcash network.
🚩 Red Flags
- High concentration risk: The company's treasury is heavily allocated to a single highly volatile digital asset (Zcash).
- Significant increase in cost basis: The latest purchase price ($602.63) is significantly higher than the previous average ($245.37), indicating aggressive buying into a rising market.
📋 Key Facts
- Purchased an additional 29,869.29 ZEC for $18 million on November 18, 2025.
- Average purchase price for this tranche: $602.63 per ZEC.
- Total cumulative holdings now stand at 233,644.56 ZEC.
- Cumulative average cost basis is $291.04 per ZEC.
- The company's total ownership of the Zcash network is now 1.43%.
- Previous acquisition (Nov 12, 2025) consisted of 203,775.27 ZEC for ~$50 million at $245.37/ZEC.
Leap Therapeutics, Inc. (now Cypherpunk Technologies Inc.) has entered into a controlled equity offering agreement with Cantor Fitzgerald & Co. to sell up to $200 million in common stock via 'at-the-market' offerings.
🚩 Red Flags
- Significant potential dilution: The $200M offering size represents a massive amount of new equity for a micro-cap company.
- At-the-market (ATM) offering: This allows the company to sell shares directly into the market, which often creates immediate downward pressure on the stock price.
📋 Key Facts
- Company name changed from Leap Therapeutics, Inc. to Cypherpunk Technologies Inc., effective Nov 12, 2025.
- Entered into a Sales Agreement with Cantor Fitzgerald & Co. on November 12, 2025.
- Aggregate offering amount of up to $200,000,000 in common stock.
- Sales will be conducted via 'at the market' offerings under an existing S-3 shelf registration (File No. 333-278015).
- Cantor Fitzgerald is entitled to a commission of up to 3.0% of gross proceeds.
Leap Therapeutics, Inc. is rebranding to Cypherpunk Technologies Inc., effective November 12, 2025. The filing details significant new compensatory arrangements including a consulting agreement with CoinXit Ltd., the appointment of a Chief Investment Officer, and massive RSU grants to directors and employees.
🚩 Red Flags
- Contingent RSU awards (totaling ~3M for CoinXit and ~5.6M for CIO) are explicitly tied to a pending reverse stock split and increase in authorized shares.
- Significant dilution risk: The filing mentions the need to increase authorized common shares to at least 490,000,000 shares to facilitate equity plans.
- Potential related-party transaction: Consulting agreement with CoinXit Ltd., where Khing Oei is the sole director/employee.
📋 Key Facts
- Company name change from Leap Therapeutics, Inc. to Cypherpunk Technologies Inc. effective Nov 12, 2025.
- Entered into a Consulting Agreement with CoinXit Ltd. (solely owned by Khing Oei) on Nov 11, 2025.
- Approved an initial award of 2,411,700 RSUs to CoinXit Ltd.; a second contingent award of 3,036,457 RSUs is pending stockholder approval of a reverse stock split and increased share authorization.
- Appointed William McEvoy as Chief Investment Officer with an annual base salary of $250,000 and target bonus of 40%.
- McEvoy to receive 5,616,906 RSUs, subject to stockholder approval of certain amendments (reverse split/share increase).
- Issued aggregate 3,241,687 RSUs to directors and employees on Nov 11, 2025.
- CEO Douglas Onsi received an award of 2,087,287 RSUs.
Leap Therapeutics announced final clinical results from Part B of its DeFianCe study, presented at the ESMO Congress 2025. The announcement was made via a press release incorporated by reference.
📋 Key Facts
- Announced final results from Part B of the DeFianCe study on October 20, 2025.
- Results were presented at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany.
- Presentation was delivered by Zev Wainberg, MD, Professor of Medicine and Co-Director of the GI Oncology Program at UCLA.
Leap Therapeutics, Inc. completed a $58.88 million private placement involving common stock and significant warrant issuances. The deal includes a strategic shift toward a 'digital asset treasury strategy' and grants the lead investor, Winklevoss Treasury Investments, LLC, substantial board representation.
🚩 Red Flags
- Massive potential dilution: The total number of shares issuable via warrants (over 152 million) significantly exceeds the current common stock issuance, posing extreme dilution risk to existing shareholders.
- Strategic pivot/Distraction: Shifting from a biotech focus toward 'digital asset treasury activities' can be viewed as a high-risk distraction from core therapeutic development.
- Significant board control shift: The Lead Investor agreement grants substantial governance rights and the ability to appoint the Board Chair.
📋 Key Facts
- Private placement gross proceeds: ~$58.88 million.
- Securities issued include 15,212,311 common shares at $0.52064/share and various pre-funded and common warrants.
- Pre-funded warrants allow for the purchase of up to 80,768,504 additional shares at a nominal price of $0.001 per share.
- Common warrants allow for the purchase of up to 71,985,605 common shares at an exercise price of $0.5335.
- Winklevoss Treasury Investments, LLC (Lead Investor) gains rights to nominate two directors if they own >16.7% and one director/chair if they own between 8.33% and 16.7%.
- The company is pivoting a portion of its treasury strategy toward 'investment in tokens and digital asset treasury activities.'
- Parcrest International acting as placement agent with $1.5 million in fees (cash and warrants).
Leap Therapeutics announced a private placement and the adoption of a digital asset treasury strategy, indicating a pivot or diversification in how the company manages its capital alongside its core biotechnology operations.
🚩 Red Flags
- Significant shift in corporate focus/treasury management (digital assets) can introduce high volatility and non-core risk to a biotech company's balance sheet.
- Private placements often involve dilution for existing shareholders.
📋 Key Facts
- Announced a private placement on October 6, 2025.
- Adopted a 'digital asset treasury strategy'.
- Intends to continue pursuing current biotechnology business line in addition to the new digital asset strategy.
Leap Therapeutics, Inc. has been granted a second 180-day grace period by Nasdaq to regain compliance with the minimum $1.00 bid price requirement. The company explicitly stated it may implement a reverse stock split to meet this requirement.
🚩 Red Flags
- Delisting notice/Non-compliance with Nasdaq minimum bid price requirement.
- Explicit mention of a potential reverse stock split to regain compliance.
- Failure to meet the initial 180-day cure period that expired on September 8, 2025.
📋 Key Facts
- Nasdaq issued a 'Second Bid Price Grace Period Letter' on September 10, 2025.
- The company has until March 9, 2026, to regain compliance with the minimum bid price requirement (Rule 5550(a)(2)).
- Compliance requires maintaining a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.
- The company has already notified Nasdaq of its intent to cure the deficiency, potentially via a reverse stock split.
Leap Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2025. The filing serves as a formal notification of the earnings release issued on August 14, 2025.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2025
- Filing date: August 14, 2025
- The filing includes the press release as Exhibit 99.1
- Ticker symbol listed in text as LPTX (Note: User prompt mentions CYPH)
Leap Therapeutics is undergoing a massive wind-down of its R&D activities, including the termination of 75% of its workforce and the cessation of its primary development programs. The company is actively seeking strategic alternatives, such as a sale, to preserve shareholder value.
🚩 Red Flags
- Massive workforce reduction (75% of staff) indicating severe distress.
- Cessation of primary R&D programs (sirexatamab and FL-501).
- Company is actively seeking a sale or liquidation to 'maximize shareholder value'.
- Significant one-time severance costs ($3.2M) impacting near-term earnings.
📋 Key Facts
- Company will complete the DeFianCe clinical trial and wind down R&D activities for sirexatamab and FL-501.
- Reduction in force (RIF) impacts approximately 75% of the current workforce.
- Estimated $3.2 million in severance and related costs to be recognized primarily in Q3 2025.
- COO Augustine Lawlor terminated effective June 30, 2025; CMO Cyndi Sirard, MD terminated on or about July 31, 2025.
- Cash and cash equivalents totaled approximately $23.3 million as of May 31, 2025.
- Engaged Raymond James & Associates, Inc. as exclusive financial advisor to explore strategic options (sale of company or assets).
Leap Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2025. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Report date: May 13, 2025
- Reporting period: Quarter ended March 31, 2025
- The company furnished its financial results through a press release (Exhibit 99.1)
- Ticker symbol listed as LPTX on Nasdaq Capital Market
Leap Therapeutics, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2024. Additionally, the company reported positive updated data from its Sirexatamab colorectal cancer study.
📋 Key Facts
- Announced Q4 and full-year 2024 financial results on March 26, 2025.
- Reported positive updated clinical data for Sirexatamab in a Colorectal Cancer study.
- Issued an updated corporate presentation via Exhibit 99.3.
Leap Therapeutics, Inc. received a deficiency notice from Nasdaq because its common stock closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until September 8, 2025, to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice/Non-compliance with minimum bid price requirement.
- Explicit mention of a potential reverse stock split as a method to regain compliance.
- Risk of permanent delisting if compliance is not met by the deadline.
📋 Key Facts
- Received Closing Bid Price Deficiency Letter from Nasdaq on March 12, 2025.
- Violation of Nasdaq Listing Rule 5550(a)(2) due to closing bid price below $1.00 for 30 consecutive business days.
- The company has a primary compliance period of 180 days ending September 8, 2025.
- Potential for an additional 180-day extension if market value requirements are met and the company files intent to cure (potentially via reverse stock split).
- Current listing status is not affected; shares continue to trade on Nasdaq Capital Market.
Leap Therapeutics, Inc. issued an 8-K to announce the release of initial clinical data from its DeFianCe (Part B) and DisTinGuish studies. The company also updated its corporate presentation.
📋 Key Facts
- Released initial clinical data from Part B of the DeFianCe Study on January 28, 2025.
- Released initial clinical data from Part C of the DisTinGuish Study on January 28, 2025.
- Updated corporate presentation was posted to the company website and filed as Exhibit 99.2.
Leap Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2024. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Report date: November 13, 2024
- Reporting period: Quarter ended September 30, 2024
- The company furnished its results of operations and financial condition in Exhibit 99.1.
Leap Therapeutics, Inc. announced the completion of enrollment in Part B of its DeFianCe Study for DKN-01, targeting colorectal cancer patients.
📋 Key Facts
- Completion of enrollment in Part B of the DeFianCe Study of DKN-01 was announced on September 30, 2024.
- The study focuses on the treatment of Colorectal Cancer patients.
- The announcement was made via a press release filed as Exhibit 99.1.
Leap Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2024. The filing serves as a formal notice that earnings data is being furnished via an accompanying press release.
📋 Key Facts
- Report date: August 12, 2024
- Reporting period: Quarter ended June 30, 2024
- The filing includes a press release as Exhibit 99.1 containing the actual financial results.
Leap Therapeutics, Inc. held its 2024 Annual Meeting of Stockholders on July 2, 2024. The filing reports the final voting results for director elections, executive compensation, equity plan amendments, and the ratification of the company's independent auditor.
📋 Key Facts
- Annual Meeting held on July 2, 2024.
- Four Class I directors were elected: James Cavanaugh, Douglas E. Onsi, Christian Richard, and Richard Schilsky.
- Stockholders approved executive compensation on an advisory basis (Say-on-Pay).
- The Amendment to the Leap Therapeutics, Inc. 2022 Equity Incentive Plan was approved.
- EisnerAmper LLP was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2024.
Leap Therapeutics, Inc. announced its financial results for the fiscal quarter ended March 31, 2024. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2024
- Filing date: May 13, 2024
- The company furnished its results through a press release (Exhibit 99.1)
Leap Therapeutics entered into a $40 million securities purchase agreement with institutional investors to issue common stock and pre-funded warrants. The proceeds are intended to fund clinical development for its lead monoclonal antibody program, DKN-01.
🚩 Red Flags
- Significant dilution potential due to the issuance of over 12.6 million shares and warrants.
- Pre-funded warrants include 'blocker' provisions (4.99% ownership limit) which are common in structured financing but can complicate cap table management.
- The transaction is a private placement, indicating the company is seeking immediate liquidity to fund ongoing clinical operations.
📋 Key Facts
- Transaction value: Approximately $40 million in gross proceeds.
- Securities issued: 12,660,993 shares of common stock at $2.82 per share and 1,523,404 pre-funded warrants.
- Pre-funded warrant price: $2.819 per warrant (equivalent to $2.82 minus $0.001 exercise price).
- Expected closing date: April 15, 2024.
- Use of proceeds: Expanding randomized controlled Part B of DeFianCe Study (colorectal cancer) from 130 to 180 patients; maturing data in DisTinGuish study (gastric cancer); manufacturing Phase 3 clinical trial material; and working capital.
- Registration rights: Company must file an S-3 registration statement for resale within 30 days of closing.
Leap Therapeutics announced its financial results for the fourth quarter and full year ended December 31, 2023. The filing serves as a formal announcement of the earnings release issued on March 18, 2024.
📋 Key Facts
- Reporting period: Fourth quarter and fiscal year ended December 31, 2023.
- Announcement date: March 18, 2024.
- The filing includes the press release as Exhibit 99.1.
Leap Therapeutics, Inc. filed an 8-K to announce the posting of an updated corporate presentation on its website.
📋 Key Facts
- The company posted an updated corporate presentation on January 23, 2024.
- The presentation is filed as Exhibit 99.1.
- The filing does not contain new material financial data or structural changes.
Leap Therapeutics, Inc. issued an 8-K to announce the release of a press statement regarding upcoming clinical data presentations at the 2024 ASCO Gastrointestinal Cancers Symposium.
📋 Key Facts
- Company will present new clinical data from Part A of the DeFianCe Study.
- Presentation is scheduled for the 2024 ASCO Gastrointestinal Cancers Symposium.
- The announcement was made via press release on January 16, 2024.